[Long-term treatment of hyperlipoproteinaemia, types IIa and IIb, with etiroxate (author's transl)].
A synthetic thyroxine derviative, etiroxate (DL-alpha-methyl-thyroxine-ethylester-CG 635) was administered to 40 patients with type IIa and 19 with type IIb hyperlipoproteinaemia for up to 390 days, 40 mg daily. It achieved a constant decrease in cholesterol of 83 mg/dl (23%) in type IIa and 64 mg/dl (18%) in types the alpha-and pre bata-lipoproteins fell when the concentration was greater than or equal to 200 mg/dl and greater than or equal to 140 mg/dl, respectively, both fractions rising when the initial concentration was below the mentioned figures. There were only slight side effects, such as gastric and autonomic nervous system symptoms. No statistically significant increase in anginal symptoms was found, even in patients with known coronary insufficiency.
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D006949:Hyperlipidemias / Q000097:blood / Q000145:classification; D008055:Lipids / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D013974:Thyroxine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D008055:Lipids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D002784:Cholesterol; D013974:Thyroxine
Langzeit-Therapie von Hyperlipoproteinamie der Typen IIa und IIb mit Etiroxat